Valproic acid after five decades of use in epilepsy: Time to reconsider the indications of a time-honoured drug

The Lancet Neurology

Volumn 15, Issue 2, 2016, Pages 210-218

  Tomson, Torbjörn ^a   Battino, Dina ^b   Perucca, Emilio ^c,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

VALPROIC ACID; ANTICONVULSIVE AGENT;

ABSENCE SEIZURE; BEHAVIORAL DEVELOPMENT; BLOOD CLOTTING DISORDER; BRAIN DISEASE; CHILD DEVELOPMENT; COGNITIVE DEVELOPMENT; CONGENITAL MALFORMATION; DEMENTIA; DISEASE PREDISPOSITION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DIZZINESS; DRUG EFFICACY; DRUG INDICATION; EPILEPSY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FOCAL EPILEPSY; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HUMAN; HYPERAMMONEMIA; HYPERANDROGENISM; HYPOCARNITINEMIA; INBORN ERROR OF METABOLISM; LIVER TOXICITY; MENSTRUAL IRREGULARITY; MOOD CHANGE; MYOCLONUS SEIZURE; OVARY POLYCYSTIC DISEASE; PREGNANCY; PRENATAL EXPOSURE; PRIMARY GENERALISED TONIC CLONIC SEIZURE; PRIORITY JOURNAL; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; THROMBOCYTE DISORDER; TREMOR; WEIGHT GAIN; ABNORMALITIES, DRUG-INDUCED; CHEMICALLY INDUCED; FEMALE;

ABNORMALITIES, DRUG-INDUCED; ANTICONVULSANTS; EPILEPSY; FEMALE; HUMANS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; VALPROIC ACID;

EID: 84955237505     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00314-2     Document Type: Review

References (96)

1. Lopez-Munoz F, Baumeister AA, Hawkins MF, Alamo C The role of serendipity in the discovery of the clinical effects of psychotropic drugs: beyond of the myth. Actas Esp Psiquiatr 2012, 40:34-42.
2. Perucca E Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002, 16:695-714.
3. Marson A, Sills G Valproate. The treatment of Epilepsy 2015, 652-666. Wiley, Oxford. 3rd edn. S. Shorvon, E. Perucca, J.J. Engel (Eds.).
4. Tomson T, Marson A, Boon P, et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia 2015, 56:1006-1019.
5. Assessment report. Procedure under Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data European Medicines Agency, (accessed April 10, 2015). http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Valproate_and_related_substances_31/Recommendation_provided_by_Pharmacovigilance:Risk_Assessment_Committee/WC500177352.pdf.
6. Van McCrary S Commentary: revised recommendation from CMDh on use of valproate in women is ethically incomplete and neglects the interests of women. Epilepsia 2015, 56:1020-1022.
7. Chateauvieux S, Morceau F, Dicato M, Diederich M Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010, 2010:479364.
8. Brodie SA, Brandes JC Could valproic acid be an effective anticancer agent? The evidence so far. Expert Rev Anticancer Ther 2014, 14:1097-1100.
9. Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013, 54:551-563.
10. Mattson RH, Cramer JA, Collins JF A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992, 327:765-771.
11. Tudur Smith C, Marson AG, Chadwick DW, Williamson PR Multiple treatment comparisons in epilepsy monotherapy trials. Trials 2007, 8:34.
12. Perucca E, Tomson T The pharmacological treatment of epilepsy in adults. Lancet Neurol 2011, 10:446-456.
13. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007, 369:1016-1026.
14. Bonnett LJ, Tudur Smith C, Smith D, Williamson PR, Chadwick D, Marson AG Time to 12-month remission and treatment failure for generalised and unclassified epilepsy. J Neurol Neurosurg Psychiatry 2014, 85:603-610.
15. Trinka E, Marson AG, Van Paesschen W, et al. KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. J Neurol Neurosurg Psychiatry 2013, 84:1138-1147.
16. Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010, 362:790-799.
17. Hancock EC, Osborne JP, Edwards SW Treatment of infantile spasms. Cochrane Database Syst Rev 2013, 6. CD001770.
18. Moshe SL, Perucca E, Ryvlin P, Tomson T Epilepsy: new advances. Lancet 2015, 385:884-898.
19. Arzimanoglou A, Ryvlin P, Perucca E When the past challenges the present: are older antiepileptic drugs still the best choice in childhood absence epilepsy?. Lancet Neurol 2010, 9:457-459.
20. Mohanraj R, Brodie MJ Outcomes of newly diagnosed idiopathic generalized epilepsy syndromes in a non-pediatric setting. Acta Neurol Scand 2007, 115:204-208.
21. Nicolson A, Appleton RE, Chadwick DW, Smith DF The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies. J Neurol Neurosurg Psychiatry 2004, 75:75-79.
22. Fattore C, Boniver C, Capovilla G, et al. A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. Epilepsia 2011, 52:802-809.
23. Trinka E, Hofler J, Zerbs A, Brigo F Efficacy and safety of intravenous valproate for status epilepticus: a systematic review. CNS Drugs 2014, 28:623-639.
24. Belcastro V, D'Egidio C, Striano P, Verrotti A Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Res 2013, 107:1-8.
25. Lonnqvist T, Paetau A, Valanne L, Pihko H Recessive twinkle mutations cause severe epileptic encephalopathy. Brain 2009, 132:1553-1562.
26. Janssen W, Quaegebeur A, Van Goethem G, et al. The spectrum of epilepsy caused by POLG mutations. Acta Neurol Belg 2015, published online June 24. 10.1007/s13760-015-0499-8.
27. Bryant AE, Dreifuss FE Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 1996, 46:465-469.
28. Dalens B, Raynaud EJ, Gaulme J Teratogenicity of valproic acid. J Pediatr 1980, 97:332-333.
29. Gomez MR Possible teratogenicity of valproic acid. J Pediatr 1981, 98:508-509.
30. Lindhout D, Schmidt D In-utero exposure to valproate and neural tube defects. Lancet 1986, 1:1392-1393.
31. Robert E, Guibaud P Maternal valproic acid and congenital neural tube defects. Lancet 1982, 2:937.
32. DiLiberti JH, Farndon PA, Dennis NR, Curry CJ The fetal valproate syndrome. Am J Med Genet 1984, 19:473-481.
33. Tomson T, Battino D Teratogenic effects of antiepileptic drugs. Lancet Neurol 2012, 11:803-813.
34. Jentink J, Loane MA, Dolk H, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 2010, 362:2185-2193.
35. Tanoshima M, Kobayashi T, Tanoshima R, Beyene J, Koren G, Ito S Risks of congenital malformations in offspring exposed to valproic acid in utero: a systematic review and cumulative meta-analysis. Clin Pharmacol Ther 2015, 98:417-441.
36. Jackson A, Bromley R, Morrow J, Irwin B, Clayton-Smith J In utero exposure to valproate increases the risk of isolated cleft palate. Arch Dis Child Fetal Neonatal Ed 2015, published online Sept 25. 10.1136/archdischild-2015-308278.
37. Tomson T, Xue H, Battino D Major congenital malformations in children of women with epilepsy. Seizure 2015, 28:40-44.
38. Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011, 10:609-617.
39. Hernandez-Diaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012, 78:1692-1699.
40. Campbell E, Kennedy F, Russell A, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry 2014, 85:1029-1034.
41. Mawhinney E, Craig J, Morrow J, et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology 2013, 80:400-405.
42. Hunt S, Russell A, Smithson WH, et al. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2008, 71:272-276.
43. Veiby G, Daltveit AK, Engelsen BA, Gilhus NE Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol 2014, 261:579-588.
44. Tomson T, Battino D, Craig J, et al. Pregnancy registries: differences, similarities, and possible harmonization. Epilepsia 2010, 51:909-915.
45. Artama M, Auvinen A, Raudaskoski T, Isojarvi I, Isojarvi J Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 2005, 64:1874-1878.
46. Canger R, Battino D, Canevini MP, et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia 1999, 40:1231-1236.
47. Cunnington MC, Weil JG, Messenheimer JA, Ferber S, Yerby M, Tennis P Final results from 18 years of the International Lamotrigine Pregnancy Registry. Neurology 2011, 76:1817-1823.
48. Dansky L Outcome of pregnancy in epileptic women. PhD thesis 1989, McGill University, Montreal.
49. Diav-Citrin O, Shechtman S, Arnon J, Ornoy A Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology 2001, 57:321-324.
50. Diav-Citrin O, Shechtman S, Bar-Oz B, Cantrell D, Arnon J, Ornoy A Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect. CNS Drugs 2008, 22:325-334.
51. Dravet C, Julian C, Legras C, et al. Epilepsy, antiepileptic drugs, and malformations in children of women with epilepsy: a French prospective cohort study. Neurology 1992, 42:75-82.
52. Fairgrieve SD, Jackson M, Jonas P, et al. Population based, prospective study of the care of women with epilepsy in pregnancy. BMJ 2000, 321:674-675.
53. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001, 344:1132-1138.
54. Kaaja E, Kaaja R, Hiilesmaa V Major malformations in offspring of women with epilepsy. Neurology 2003, 60:575-579.
55. Kaneko S, Otani K, Fukushima Y, et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia 1988, 29:459-467.
56. Koch S, Losche G, Jager-Roman E, et al. Major and minor birth malformations and antiepileptic drugs. Neurology 1992, 42:83-88.
57. Lander CM, Eadie MJ Antiepileptic drug intake during pregnancy and malformed offspring. Epilepsy Res 1990, 7:77-82.
58. Mawer G, Briggs M, Baker GA, et al. Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. Seizure 2010, 19:112-119.
59. Meischenguiser R, D'Giano CH, Ferraro SM Oxcarbazepine in pregnancy: clinical experience in Argentina. Epilepsy Behav 2004, 5:163-167.
60. Melchior JC, Svensmark O, Trolle D Placental transfer of phenobarbitone in epileptic women, and elimination in newborns. Lancet 1967, 2:860-861.
61. Millar JH, Nevin NC Congenital malformations and anticonvulsant drugs. Lancet 1973, 1:328.
62. Nulman I, Scolnik D, Chitayat D, Farkas LD, Koren G Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. Am J Med Genet 1997, 68:18-24.
63. Omtzigt JG, Los FJ, Grobbee DE, et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992, 42:119-125.
64. Ornoy A, Cohen E Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Arch Dis Child 1996, 75:517-520.
65. Ornoy A, Zvi N, Arnon J, Wajnberg R, Shechtman S, Diav-Citrin O The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies. Reprod Toxicol 2008, 25:388-389.
66. Samrén EB, van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997, 38:981-990.
67. Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology 2015, 85:866-872.
68. Viinikainen K, Heinonen S, Eriksson K, Kalviainen R Community-based, prospective, controlled study of obstetric and neonatal outcome of 179 pregnancies in women with epilepsy. Epilepsia 2006, 47:186-192.
69. Waters CH, Belai Y, Gott PS, Shen P, De Giorgio CM Outcomes of pregnancy associated with antiepileptic drugs. Arch Neurol 1994, 51:250-253.
70. Wide K, Winbladh B, Kallen B Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr 2004, 93:174-176.
71. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999, 33:145-158.
72. Holmes LB, Mittendorf R, Shen A, Smith CR, Hernandez-Diaz S Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Arch Neurol 2011, 68:1275-1281.
73. Vajda FJ, Hitchcock AA, Graham J, O'Brien TJ, Lander CM, Eadie MJ The teratogenic risk of antiepileptic drug polytherapy. Epilepsia 2010, 51:805-810.
74. Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004, 75:1575-1583.
75. Cohen MJ, Meador KJ, Browning N, et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy Behav 2011, 22:240-246.
76. Cohen MJ, Meador KJ, Browning N, et al. Fetal antiepileptic drug exposure: adaptive and emotional/behavioral functioning at age 6 years. Epilepsy Behav 2013, 29:308-315.
77. Meador KJ, Baker GA, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009, 360:1597-1605.
78. Meador KJ, Baker GA, Browning N, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol 2013, 12:244-252.
79. Meador KJ, Baker GA, Browning N, et al. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain 2011, 134:396-404.
80. Baker GA, Bromley RL, Briggs M, et al. IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology 2015, 84:382-390.
81. Bromley RL, Mawer G, Love J, et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia 2010, 51:2058-2065.
82. Shallcross R, Bromley RL, Cheyne CP, et al. In utero exposure to levetiracetam vs valproate: development and language at 3 years of age. Neurology 2014, 82:213-221.
83. Cummings C, Stewart M, Stevenson M, Morrow J, Nelson J Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child 2011, 96:643-647.
84. Bromley R, Weston J, Adab N, et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst Rev 2014, 10. CD010236.
85. Williams G, King J, Cunningham M, Stephan M, Kerr B, Hersh JH Fetal valproate syndrome and autism: additional evidence of an association. Dev Med Child Neurol 2001, 43:202-206.
86. Wood AG, Nadebaum C, Anderson V, et al. Prospective assessment of autism traits in children exposed to antiepileptic drugs during pregnancy. Epilepsia 2015, 56:1047-1055.
87. Christensen J, Gronborg TK, Sorensen MJ, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 2013, 309:1696-1703.
88. Campbell E, Devenney E, Morrow J, et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia 2013, 54:165-171.
89. Vajda FJ, O'Brien TJ, Lander CM, Graham J, Roten A, Eadie MJ Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia 2013, 54:181-186.
90. Begum S, Sarma SP, Thomas SV Malformation in index pregnancy in women with epilepsy is not followed by recurrence in subsequent pregnancy. Epilepsia 2013, 54:e163-e167.
91. Zhang X, Pei L, Li R, et al. Spina bifida in fetus is associated with an altered pattern of DNA methylation in placenta. J Hum Genet 2015, 60:605-611.
92. Budi T, Toth K, Nagy A, et al. Clinical significance of CYP2C9-status guided valproic acid therapy in children. Epilepsia 2015, 56:849-855.
93. Edey S, Moran N, Nashef L SUDEP and epilepsy-related mortality in pregnancy. Epilepsia 2014, 55:e72-e74.
94. MacDonald SC, Bateman BT, McElrath TF, Hernandez-Diaz S Mortality and morbidity during delivery hospitalization among pregnant women with epilepsy in the United States. JAMA Neurol 2015, 72:981-988.
95. Battino D, Tomson T, Bonizzoni E, et al. Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry. Epilepsia 2013, 54:1621-1627.
96. Perucca E, Battino D, Tomson T Gender issues in antiepileptic drug treatment. Neurobiol Dis 2014, 72 Pt B:217-223.